 KEAPSAKE is a Phase 2 randomized trial evaluating telaglenastat with chemoimmunotherapy in front-line among patients with non-small cell lung cancer and a mutation in the KEAP1NRF2 pathway KEAPSAKE is a Phase 2 randomized trial evaluating telaglenastat with chemoimmunotherapy in front-line among patients with non-small cell lung cancer and a mutation in the KEAP1NRF2 pathway 